Litigation Details for WARNER CHILCOTT COMPANY, LLC v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2011)

WARNER CHILCOTT COMPANY, LLC v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2011)

Docket		Date Filed	2011-11-22
Court	District Court, D. New Jersey	Date Terminated	2015-03-04
Cause	35:271 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	7,645,459; 7,645,460; 8,246,989
Link to Docket	External link to docket

Details for WARNER CHILCOTT COMPANY, LLC v. TEVA PHARMACEUTICALS USA, INC. (D.N.J. 2011)

Date Filed	Document No.	Description	Snippet	Link To Document
2011-11-22				External link to document

Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc. Litigation Summary and Patent Analysis

Last updated: August 12, 2026

Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc., No. 2:11-cv-06936, was an Abbreviated New Drug Application (ANDA) patent case in the U.S. District Court for the District of New Jersey involving Teva's proposed generic version of Doryx, Warner Chilcott's delayed-release doxycycline hyclate product. The dispute concerned formulation patents covering delayed release, particle-size control, and oral doxycycline delivery. The case formed part of Warner Chilcott's broader strategy to protect Doryx from generic competition through Orange Book-listed formulation patents.

The litigation was commercially significant because Doryx was a branded, modified-release antibiotic with limited clinical differentiation from conventional doxycycline. Its protection depended primarily on formulation and manufacturing patents rather than composition-of-matter exclusivity.

What drug and patents were involved in Warner Chilcott v. Teva?

The case involved Doryx delayed-release tablets, whose active ingredient is doxycycline hyclate. Doryx is an oral tetracycline antibiotic approved for acne and other bacterial infections.

Warner Chilcott's patent position relied on patents directed to delayed-release doxycycline formulations and the physical characteristics of doxycycline particles. The relevant Doryx patent family included the following U.S. patents:

Patent	General subject matter	Relevance to Doryx
U.S. Patent No. 6,958,161	Delayed-release doxycycline formulation	Core formulation protection
U.S. Patent No. 7,232,572	Pharmaceutical composition containing doxycycline	Formulation and release profile protection
U.S. Patent No. 6,911,217	Doxycycline formulation technology	Related product protection
Later continuation patents	Modified-release tablets and manufacturing features	Follow-on protection and Orange Book coverage

The patents did not protect doxycycline itself. Doxycycline is an old antibiotic with no meaningful remaining composition-of-matter exclusivity. The litigation therefore focused on whether Teva's proposed product would practice Warner Chilcott's formulation claims and whether those claims were valid and enforceable.

Patent scope varied by claim. Some claims focused on a delayed-release dosage form. Others addressed the use of doxycycline particles with specified size distributions or a particular combination of immediate-release and delayed-release components.

What was the legal basis of Warner Chilcott's lawsuit?

Warner Chilcott sued after receiving notice that Teva had filed an ANDA seeking FDA approval for a generic doxycycline hyclate delayed-release product. Warner Chilcott alleged that filing the ANDA was an artificial act of infringement under 35 U.S.C. § 271(e)(2).

The usual ANDA litigation issues applied:

1. Whether Teva's proposed generic would infringe the asserted Doryx patents.
2. Whether the patent claims were invalid for anticipation or obviousness.
3. Whether the patents were unenforceable because of inequitable conduct.
4. Whether Warner Chilcott was entitled to an injunction preventing FDA approval or commercial launch.
5. Whether Teva's Paragraph IV certification triggered the Hatch-Waxman 30-month stay.

The case was not a conventional commercial patent dispute involving an already marketed generic. The principal infringement theory was based on Teva's ANDA filing and proposed product specifications.

What was the procedural history of the case?

The case was filed in the District of New Jersey in 2011. Warner Chilcott asserted Doryx-related patents against Teva in response to Teva's ANDA filing.

The litigation involved the standard phases of an ANDA case:

Phase	Issue
Complaint	Warner Chilcott alleged infringement based on Teva's ANDA
Claim construction	The court interpreted technical terms in the delayed-release and particle-size claims
Fact and expert discovery	The parties addressed formulation design, manufacturing processes, and prior art
Invalidity and infringement analysis	Teva challenged claim scope and validity
Settlement or final disposition	The docket ultimately closed without a reported merits judgment establishing broad invalidity of the Doryx patent estate

Publicly available case materials identify the matter as an ANDA dispute rather than a post-launch damages case. The case should be analyzed together with related Doryx litigation against other generic manufacturers because Warner Chilcott pursued overlapping patent claims across multiple ANDA defendants.

What patent issues were most important in the Doryx litigation?

Delayed-release formulation claims

Doryx uses a delayed-release delivery system intended to reduce immediate dissolution of doxycycline in the stomach and control release in the gastrointestinal tract. The legal value of these claims depended on how narrowly the court construed terms describing release timing, coatings, layers, and dosage-form architecture.

A narrow construction could allow Teva to design around the claims. A broader construction could make infringement more likely but increase exposure to invalidity attacks based on earlier delayed-release doxycycline products and other modified-release drug technologies.

Particle-size and dissolution limitations

Doxycycline particle characteristics can affect dissolution rate, stability, manufacturability, and release behavior. Warner Chilcott's patent strategy used physical-property limitations to distinguish Doryx from conventional doxycycline products.

These claims created two litigation risks. First, particle-size limitations can be difficult to enforce if the accused product's characteristics vary by batch. Second, similar particle engineering concepts were known in pharmaceutical formulation, giving Teva potential obviousness arguments.

Obviousness

Teva's principal invalidity position would have focused on whether a skilled pharmaceutical formulator could have combined known doxycycline particles, enteric coatings, delayed-release layers, and tablet manufacturing methods with a reasonable expectation of success.

The strength of Warner Chilcott's response depended on evidence that the claimed combination produced an unexpected dissolution profile, improved tolerability, or solved a specific manufacturing problem. Commercial success alone would have carried limited weight without a demonstrated nexus to the patented features.

Infringement under the ANDA statute

For an ANDA case, Warner Chilcott did not need to wait for Teva to sell a generic product. The filing itself created the statutory act of infringement. The dispute therefore centered on Teva's proposed product and certification, not on actual commercial batches sold in the market.

Did Teva file a Paragraph IV challenge?

Yes. The litigation arose from Teva's ANDA and Paragraph IV certification concerning Warner Chilcott's Doryx patents. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product.

The certification produced several consequences:

• Warner Chilcott had a 45-day period to file suit.
• FDA approval of Teva's ANDA was generally subject to the Hatch-Waxman 30-month stay.
• Teva became exposed to patent infringement liability under § 271(e)(2).
• Teva could seek an earlier launch through a successful invalidity or noninfringement judgment, a settlement, or expiration of the stay.

The Paragraph IV challenge was commercially important because doxycycline itself was generic, but Doryx's delayed-release formulation remained protected by secondary patents.

What was the Orange Book status of Doryx?

Doryx's Orange Book protection consisted of formulation and method-related listings rather than a basic active-ingredient patent. Listed patents for Doryx and related doxycycline delayed-release products changed over time as Warner Chilcott and its successors added continuation patents and obtained approvals for different strengths and dosage forms.

The principal Orange Book categories were:

Protection type	Doryx relevance
Active ingredient	Minimal; doxycycline is an old generic antibiotic
Dosage form	High; delayed-release tablets were central to the product
Formulation	High; coatings, layers, and release characteristics were key
Manufacturing process	Potentially significant, but enforcement depends on whether the process is reflected in the ANDA
Method of use	Secondary; the principal commercial defense was formulation protection

Orange Book listing did not establish patent validity. It allowed Warner Chilcott to invoke the Hatch-Waxman litigation and approval-delay mechanisms.

When did Doryx lose exclusivity?

Doryx lost exclusivity progressively rather than on a single date.

Exclusivity category	Commercial effect
Doxycycline composition exclusivity	Long expired before this litigation
FDA drug exclusivity	Not the primary barrier in the Teva case
Core formulation patents	Main basis for delayed generic entry
Later continuation patents	Extended protection for particular strengths or product configurations
Patent litigation stay	Delayed approval while the case was pending

Doryx's protection was therefore dependent on patent-by-patent expiration and the scope of Teva's proposed product. A generic could enter once it obtained approval, avoided valid claims, prevailed in litigation, or reached a settlement permitting launch.

Did the case produce a published patent-infringement judgment?

No reported decision from this docket established a broad final ruling invalidating the Doryx patent estate or finding that Teva's product infringed every asserted patent. The case is best understood as part of Warner Chilcott's multi-defendant ANDA enforcement program.

The absence of a published merits judgment does not mean the patents were definitively upheld. It means the docket did not produce a widely reported final merits opinion comparable to a Federal Circuit decision on the full Doryx estate.

The commercial result must therefore be separated from the legal result. A settlement, dismissal, or negotiated launch date can preserve patent value without producing a judicial finding that the claims are valid.

What settlement issues mattered commercially?

A Doryx settlement would typically address:

• The earliest date Teva could launch.
• Whether launch could occur before all listed patents expired.
• The dosage strengths and formulations Teva could market.
• Whether Teva could launch an authorized generic arrangement.
• Allocation of launch risk if another generic entered first.
• Dismissal of infringement claims and release of related causes of action.
• Treatment of future continuation patents.

The economic value of a settlement depended on Doryx sales, the number of competing ANDA filers, the remaining patent term, and the likelihood that a competitor could design around Warner Chilcott's claims.

Because doxycycline has many generic alternatives, the settlement value was tied to the premium associated with the delayed-release product rather than to control of the entire doxycycline market.

How strong was Warner Chilcott's Doryx patent estate?

The estate was moderately strong as a regulatory-delay tool but weaker as a monopoly over doxycycline.

Its strengths were:

• Multiple formulation patents.
• Orange Book listing and Hatch-Waxman enforcement rights.
• Product-specific delayed-release architecture.
• Potentially difficult-to-detect formulation characteristics.
• Continuation filings that could cover later product variations.

Its weaknesses were:

• No meaningful active-ingredient exclusivity.
• Heavy reliance on secondary formulation claims.
• Exposure to obviousness challenges based on known modified-release technology.
• Potential design-around options for generic manufacturers.
• Limited ability to block conventional immediate-release doxycycline products.

The estate's practical value depended on whether Teva's ANDA product reproduced the specific release mechanism and particle characteristics claimed in the patents. A generic could avoid some claims through a different coating system, tablet architecture, or dissolution profile.

What generic-entry risks existed for Warner Chilcott?

The primary risk was rapid erosion after the first approved generic delayed-release doxycycline product entered the market. Doryx's price premium depended on its modified-release formulation and physician familiarity, but payers could substitute lower-cost doxycycline products where clinical requirements permitted.

The principal entry scenarios were:

Scenario	Effect on Warner Chilcott
Teva wins on invalidity	Immediate or accelerated generic entry
Teva wins on noninfringement	Entry without a final patent defeat
Settlement with licensed launch date	Predictable erosion beginning on the agreed date
Teva delays launch	Continued branded sales, but with litigation cost
Design-around approval	Generic competition against the specific Doryx formulation
Multiple generic approvals	Faster price and volume erosion

Warner Chilcott's exposure was greater if several generic companies challenged the same patents. The first challenger could obtain a commercial advantage, while later entrants could accelerate market fragmentation.

Did biosimilar risk apply to this case?

No. Doryx is a small-molecule doxycycline product, not a biologic. The relevant competitors were ANDA filers seeking abbreviated approval for generic doxycycline delayed-release tablets.

The governing framework was Hatch-Waxman, including Paragraph IV certifications, the 30-month stay, and possible 180-day first-filer exclusivity. The Biologics Price Competition and Innovation Act and biosimilar interchangeability rules were not relevant.

What is the competitive landscape for Doryx?

The competitive landscape included:

• Branded Doryx and later Warner Chilcott or successor products.
• Generic delayed-release doxycycline products.
• Conventional immediate-release doxycycline hyclate.
• Other tetracycline-class antibiotics used for acne and infection.
• Competing branded acne therapies with different delivery systems.

The patent dispute protected a specific delivery format. It did not prevent substitution with other doxycycline products or unrelated acne therapies.

Key Takeaways

• Warner Chilcott v. Teva, No. 2:11-cv-06936, was an ANDA Paragraph IV case involving Doryx delayed-release doxycycline.
• Warner Chilcott relied on formulation, delayed-release, particle-size, and related secondary patents.
• Doxycycline's active ingredient was long generic; the dispute concerned the Doryx delivery system.
• The case did not produce a reported broad merits ruling invalidating or sustaining the entire Doryx patent estate.
• Doryx's commercial protection depended on Orange Book-listed formulation patents, litigation timing, and settlement terms.
• Generic entry risk was substantial because alternative doxycycline products were already available.
• Biosimilar analysis was irrelevant because Doryx is a small-molecule drug.
• The patent estate was more effective at delaying product-specific generic entry than at blocking competition in the broader doxycycline market.

FAQs

What company owned the Doryx patents?

Warner Chilcott was the principal branded-product company involved in the litigation. Ownership, licensing, and enforcement rights could vary among Warner Chilcott affiliates and successor entities over the life of the patent portfolio.

Was Doryx protected by a composition-of-matter patent?

No meaningful composition-of-matter protection remained for doxycycline when the Teva litigation was filed. The relevant protection covered delayed-release formulation and product-design features.

Could Teva market immediate-release doxycycline after the Doryx lawsuit?

Yes. Doryx patents did not generally block conventional immediate-release doxycycline products that did not practice the asserted delayed-release claims.

What made Doryx different from ordinary doxycycline tablets?

Doryx used a delayed-release formulation intended to control doxycycline release and reduce immediate exposure in the upper gastrointestinal tract. The formulation, rather than the antibiotic molecule, was the principal basis for patent protection.

Did Warner Chilcott's Doryx patents block all generic doxycycline products?

No. The patents targeted the Doryx delayed-release product and related formulations. They did not create a monopoly over all doxycycline products.

References

1. U.S. District Court for the District of New Jersey. (2011). Warner Chilcott Company, LLC v. Teva Pharmaceuticals USA, Inc., No. 2:11-cv-06936.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA, Orange Book.

3. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,911,217: Doxycycline formulations.

4. U.S. Patent and Trademark Office. (2005). U.S. Patent No. 6,958,161: Doxycycline formulations.

5. U.S. Patent and Trademark Office. (2007). U.S. Patent No. 7,232,572: Pharmaceutical compositions comprising doxycycline.

6. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355(j).

7. Patent Act, 35 U.S.C. § 271(e)(2).